Spero Therapeutics
SPRO· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +126.2% in FY2025
Esther Rajavelu is the CEO of Spero Therapeutics and was paid $2.1M in FY2025 (Dec), up 141%.
Pay$100 in the stock at the end of FY22 → $135
Executives3
See all- 1Esther RajaveluPresident and Chief Executive Officer, Chief Financial Officer, Chief Business Officer and TreasurerFY2025
- 2Satyavrat ShuklaFormer President and Chief Executive OfficerFY2025
- 3Timothy KeutzerChief Operating OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allSpero Therapeutics paid its 3 named executives $5.5M in total in FY2025 (Dec). CEO Esther Rajavelu was paid $2.1M of that.
| Name | |||
|---|---|---|---|
| Esther RajaveluPresident and Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer | |||
| Satyavrat ShuklaFormer President and Chief Executive Officer | |||
| Timothy KeutzerChief Operating Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Spero Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board3
See all- John C. Pottage, Jr., M.D.Director · 5 yr on the boardIndependentAudit—Paid as an executive
- Cynthia SmithDirector · 4 yr on the boardIndependentCompensation (Chair)—Paid as an executive
- Kathleen TregoningDirector · 2 yr on the boardIndependentCompensation—Paid as an executive
The board of the latest proxy (FY2023).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 27, 2026 | FY2025 |
| Annual report | 10-K | Mar 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 28, 2025 | FY2024 |
| Annual report | 10-K | Mar 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 16, 2024 | FY2023 |
| Annual report | 10-K | Mar 13, 2024 | FY2023 |
